Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2017, Vol. 44 Issue (3): 384-391    DOI: 10.12891/ceog3721.2017
Original Research Previous articles | Next articles
IVIg therapy increases delivery birthweight in babies born to women with elevated preconception proportion of peripheral blood (CD56+/CD3-) natural killer cells
J.L. Reed1, *(), E.E. Winger1
1 Laboratory for Reproductive Medicine and Immunology, San Jose, CA, USA
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  Summary: In this study, the authors investigated: (1) whether elevated preconception peripheral blood proportion of CD56+ /CD3- lymphocytes (NK cells) was associated with low delivery birthweight in high risk women, and (2) whether intravenous immunoglobulin (IVIg) therapy could be used to improve the delivery outcome in these women. Materials and Methods: Sixty-six women who had singleton deliveries were divided into four groups. Group 1: 16 women with elevated preconception NK cells (>12%) using IVIg, group 2: eight women with similar elevated preconception NK cells not using IVIg, group 3: 32 women with non-elevated preconception NK cells (≤ 12%) using IVIg, and group IV: ten women with similar non-elevated preconception NK cells not using IVIg. These groups were similar with regards to patient age, test results, and history. Results: Mean gestational age (±SD) of babies at delivery was 39.3 ± 1.7, 37.4 ± 3.7, 38.5 ± 1.3, and 38.7 ± 1.5 weeks, for groups 1, 2, 3 and 4, respectively. Mean birthweight of babies at delivery was 3,267 ± 373, 2,654 ± 627, 3,129 ± 527, and 3,202 ± 357 grams, respectively. Birthweight was significantly higher for group 1 vs. group 2 (p = 0.006) but not for groups 1 vs. group 3. There was no significant difference between the groups for preeclampsia rate, C-section rate or preterm delivery rate. Conclusion: In women with elevated preconception peripheral NK cells, mean birthweight at delivery is low without IVIg therapy (2,654 ± 627 grams) but significantly improved with IVIg therapy (3,267 ± 373 grams). In high risk women without preconception NK cell elevation, mean birthweight at delivery is not further increased with IVIg therapy (3,202 ± 357 grams with IVIg vs. 3,129 ± 527 grams without IVIg). IVIg may be a treatment option for women with preconception NK elevation at risk of a low birthweight baby. Preconception immune testing may be a tool for determining which patients will benefit from IVIg therapy. Larger repeat studies are needed for confirmation.
Key words:  IUGR      IVIg      Low birthweight      Natural killer cell      Preeclampsia      Preterm delivery     
Published:  10 June 2017     
*Corresponding Author(s):  J.L. REED     E-mail:  reedjanel@yahoo.com

Cite this article: 

J.L. Reed, E.E. Winger. IVIg therapy increases delivery birthweight in babies born to women with elevated preconception proportion of peripheral blood (CD56+/CD3-) natural killer cells. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(3): 384-391.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3721.2017     OR     https://ceog.imrpress.com/EN/Y2017/V44/I3/384

[1] Luca Roncati, Greta Gianotti, Elisa Ambrogi, Giovanna Attolini. COVID-19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 778-780.
[2] Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina. Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 812-819.
[3] Shingo Tanaka, Maki Goto, Saya Watanabe, Sachino Kira, Sotaro Hayashi, Shigeki Fujimoto, Miho Oda, Lifa Lee, Yoko To, Satoshi Nishiyama, Fuyuki Eguchi, Hiroshi Tsujioka. Posterior reversible encephalopathy syndrome with reversible cerebral vasoconstriction syndrome in a normal primigravida woman at the 35-week gestational stage: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 982-986.
[4] Lejla Kamerić, Anis Cerovac, Mirzeta Rizvanović, Alen Kamerić, Mahira Jahić, Dubravko Habek. Frequency of cesarean section in pregnant women with risk factors for preeclampsia: prospective cohort study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 561-566.
[5] Elisa Casella, Carla Ettore, Ferdinando Antonio Gulino, Elisa Pappalardo, Filippo Rapisarda, Stella Capriglione, Giuseppe Ettore. Two successful pregnancies after a simultaneous kidney and pancreas transplantation for type 1 diabetes mellitus-complicated nephropathy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 697-699.
[6] Yi Zhou, Ran Wang, Shi-Xian Chen, Li-Sheng Wu, Jun-Qing Zhu. Matrix metalloproteinase 9 gene promoter region -1562 C/T single nucleotide polymorphism increases the susceptibility to hypertensive disorders of pregnancy: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 245-252.
[7] Jing Wang, Min Zhou, Li Zhang, Long-Xin Zhang. Effective doses 50% and 95% of subarachnoid injection of sufentanil with ropivacaine in lumbar anesthesia for cesarean section in severe preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 105-109.
[8] R. Mihăilă. Coagulation challenges in pregnancy: from thrombophilia involvement and management to the utility of thrombin generation monitoring[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 814-820.
[9] N. Dropińska, K. Chmaj-Wierzchowska, M. Wojciechowska, M. Wilczak. What is the state of knowledge on preterm birth?[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 505-510.
[10] H.M. Kim, Y.S. Choo, W.J. Seong. Serum NT-proBNP levels as a marker for cardiopulmonary function in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 511-515.
[11] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[12] A. E. Kholeif, M. Y. Khamis, S. Eltabakh, R. S. Swilam, A. Elhabashy, R. EISherif. Prediction of severity of preeclampsia in Egyptian patients: role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and C-reactive protein[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 183-188.
[13] C. Chollet, B. Andre, M. Voglimacci, A. Ghassani, O. Parant, P. Guerby. Perinatal outcomes of second trimester antenatal genital bleeding[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 105-110.
[14] R. Csorba, P. Tsikouras, A. Bothou, S. Zervoudis, G. Iatrakis, X. Anthoulaki, D. Deuteraiou, A. Chalkidou, G. F. von Tempelhoff. Air travel during pregnancy: an update review and practical recommendation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 862-866.
[15] J. Yoon Park, S.W. Lee, K.J. Oh, J.-S. Hong. High mean blood pressure during the first trimester is predictive of future preeclampsia development in healthy pregnant women: a cohort study in Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 770-775.
No Suggested Reading articles found!